TickerTalks
Browse all tickers →
TickerTalks›$TECH
TETECH

Bio-Techne Corporation

$TECH·$11B·Biotechnology·Healthcare
$70.92+0.3%YTD+20.2%1Y+36.2%
Mentions · last 7 days
2026-06-19: 1 posts2026-06-20: 0 posts2026-06-21: 4 posts2026-06-22: 7 posts2026-06-23: 4 posts2026-06-24: 4 posts2026-06-25: 143 posts163
Price updated 4m ago·X counts updated 20h ago
TETECH
$TECHBio-Techne Corporation
$70.92+0.30%163 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $TECH, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-06-26

The move is getting stronger, with heavier trading behind it.

Bio-Techne +20% in a single day on no flagged news — life-sciences-tools recovery may finally be inflecting.

Bio-Techne develops life-science reagents, instruments, and services for research, diagnostics, and bioprocessing customers. The stock just had a one-day +20% move with no flagged news in the bundle — that's the kind of move that suggests a major reported development or sector-wide bid that bears watching.

  • The fundamentals are still in cyclical chop: Q1 (March 2026) revenue declined 1.5% YoY to $311M with operating margin at 24% — the trailing four-quarter sequence runs -1%, -0.4%, -1%, +3.5%, so the day's +20% pop suggests the market is anticipating a Q2-or-FY27 inflection that the trailing data doesn't yet show.
  • Consensus has FY26 revenue at $1.21B and FY27 EPS at $2.06 — at the current ~$71 price, that's a forward PE near 34x, demanding multiple for a low-growth life-sciences-tools business unless the recovery actually inflects.
  • Insider activity is minimal: officer Crouse's small June 4 exercise/withholding events are tax-related — for a $11B life-sciences-tools company, the absence of meaningful insider selling is the absence-of-bear-signal at the rerate level.
  • The structural setup is the life-sciences-tools-recovery thesis: post-pandemic capex digestion in pharma R&D and biotech-funding constraints have weighed on the cohort (TMO, A, DHR all soft), so any sign that biotech-funding is recovering or pharma-R&D budgets are reaccelerating lifts the entire group with TECH as a smaller-cap beneficiary.

What extends the move past $80 is the next earnings print confirming the +3.5% Q1 trajectory accelerates plus visible bioprocessing-segment revenue contribution — that's the path that justifies the +20% one-day move. What invalidates the run is a return to revenue decline in Q2 or commentary that biotech-funding constraints persist; at the 100x trailing PE and the chart already extended on the day, the room for disappointment is small.

What to watch: Next quarterly earnings — revenue growth trajectory (must extend the Q1 +3.5% YoY inflection), bioprocessing segment commentary, and any update on pharma-R&D and biotech-funding demand. A clean print extends the rerate; another revenue-decline quarter compresses the chart back from the post-pop level.

On the calendar: Next earnings (timing TBD)

one day pop unexplainedno x sentimentlife sciences tools recovery

Read the AI verdict + X sentiment for $TECH

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $TECH.

Biotechnology · Healthcare

GLP-1 pipeline competition is the dominant structural driver — the ADA conference crystallized oral formulations, dual agonists, and differentiated mechanisms competing for a potential $150B obesity market by 2030. QURE's FDA accelerated approval for AMT-130 (Huntington's disease) this week confirms gene therapy regulatory momentum is still flowing capital to non-GLP-1 precision medicine.

Top industry ETF

$IBBiShares Biotechnology ETF
+8.3%YTD
+45.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
99.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
4.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
12.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
9.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
5.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
65.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q3 FY26$311.4M-1.5%66.9%24.2%$0.33$77.6M
Q2 FY26$295.9M-0.4%64.6%18.4%$0.24$76.5M
Q1 FY26$286.6M-1.0%65.6%16.6%$0.25$22.2M
Q4 FY25$317.0M+3.5%62.7%-7.5%$-0.11$93.3M

Forward consensus

5-year forecast · up to 11 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.2B$1.2B – $1.2B$1.92$1.86 – $1.9511
FY27$1.3B$1.2B – $1.3B$2.06$1.94 – $2.1510
FY28$1.4B$1.4B – $1.4B$2.33$2.18 – $2.509
FY29$1.5B$1.5B – $1.5B$2.67$2.62 – $2.724
FY30$1.6B$1.5B – $1.6B$2.66$2.61 – $2.705

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 8Amy E. HerrDirector6.6K sh$320KSellFeb 17Amy E. HerrDirector2.0K sh$117K
+ 24 other (12 exempts · 11 inkinds · 1 award) in window

See when $TECH insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$DFTX$APGE$IBRX$QURE$PRAX$INSM$REPL
Voices on X · last 7 days

No standout posts about $TECH on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport